Indication / Asset | Known Activity | Discovery | Hit to Lead | Lead | IND | Phase 1 | Phase 2 | Phase 3 | ||
Clinical Programs | ||||||||||
Glioblastoma (GBM)BPM31510-IV | Radiation Sensitizer | |||||||||
Pancreatic CancerBPM31510-IV | Chemotherapy Sensitizer | |||||||||
Primary CoQ10 DeficiencyBPM31510-IV | Direct Replacement | A phase 3 trial is being planned | ||||||||
Squamous Cell Carcinoma BPM31510-T | Wound Healing | |||||||||
Epidermolysis BullosaBPM31510-T | Wound Healing | |||||||||
SarcopeniaBPM31510-Oral | Mitochondrial Respiration | |||||||||
Solid and Liquid Tumors BRG399 | Tubulin Polymerization | |||||||||
Secondary CVD Prevention BRG399 | Neutrophil Inflammation | |||||||||
BPM31510, has received FDA Rare Pediatric Disease Designation for Primary Coenzyme Q10 Deficiency (PCQD) and Epidermolysis Bullosa (EB) respectively. The company is planning a potential pivotal trial in Primary CoQ10 Deficiency. Upon Approval, both designations provide BPGbio eligibility for a Priority Review Voucher (PRV). | ||||||||||
